NCT06845202: An ongoing trial by Alnylam Pharmaceuticals
This trial is ongoing. It must report results 2 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06845202 |
|---|---|
| Title | A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 3, 2025 |
| Completion date | Aug. 31, 2027 |
| Required reporting date | Aug. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |